The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Optimizing diagnosis and treatment of NK/T-cell lymphoma
Shinichi Makita, MD, National Cancer Center Hospital, Tokyo, Japan, comments on the importance of accurate and early diagnosis of NK/T-cell lymphoma, highlighting the value of pathological review by an experienced hematopathologist. Dr Makita encourages clinicians to consider referring patients to clinical trials for first-line treatment, as novel immunotherapies may offer meaningful benefits for patients with limited treatment options. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
